Carl June Weighs in on FDA’s Cell and Gene Therapy Round Table  

Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine highlighted the lengthy and costly clinical approval process in the US and suggested a two-tier model for clinical trials at an FDA roundtable with life science researchers, entrepreneurs, and US health agency heads working in the cell and gene therapy field.  Read more here.